1,688
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Bayer's recently active trials. Comparator arms are excluded.
- ADT5 trials
- Finerenone4 trials
- Riociguat (Adempas, BAY63-2521)4 trials
- Pembrolizumab3 trials
- Vericiguat (Verquvo, BAY1021189)3 trials
- Darolutamide (Nubeqa, BAY1841788)3 trials
Upcoming readouts
Next primary completion dates among Bayer's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Mar 2027exPDite-2: A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's D…Phase 3
- Oct 2027SOHO-02: A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standar…Phase 3
- Nov 2027ASSESS: A Study to Learn About How Well BAY 3401016 Works in Adults With Alport SyndromePhase 2
- Aug 2028FIONA OLE: A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Tak…Phase 3
- Aug 2028REGENERATE-PD: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)Phase 2
- Oct 2028CHINANEO: A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) W…Phase 2
Top therapeutic areas
Conditions studied most often across Bayer's recently active trials.
- Chronic Kidney Disease8 trials
- Hemophilia A7 trials
- Type 2 Diabetes Mellitus5 trials
- Children4 trials
- Advanced Solid Tumors4 trials
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)3 trials
Bayer pipeline by phase
The main study drugs across 61 active trials Bayer leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 37 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Finerenone (Kerendia, BAY94-8862) | 5 | 4 | Apr 2027 est. | NCT07192952 · NCT07188805 · NCT05457283 |
| SevabertinibBAY2927088 | 2 | 2 | Oct 2027 est. | NCT06452277 · NCT06760819 |
| BAY3723113 | 1 | — | — | NCT07023341 |
| bemdaneprocel | 1 | 1 | Mar 2027 est. | NCT06944522 |
| Darolutamide (BAY1841788, Nubeqa) | 1 | — | Jul 2027 est. | NCT05794906 |
| Elinzanetant (BAY3427080) | 1 | — | — | NCT05587296 |
| Riociguat (Adempas, BAY63-2521) | 1 | — | — | NCT02562235 |
Phase 27 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| AB-1005 | 2 | — | Apr 2028 est. | NCT07566429 · NCT07215403 |
| AAV2-GDNF gene therapy | 1 | 1 | Aug 2028 est. | NCT06285643 |
| AB-1002 | 1 | — | Oct 2026 est. | NCT05598333 |
| BAY 3401016 | 1 | 1 | Nov 2027 est. | NCT07211685 |
| BAY 3670549 | 1 | 1 | May 2030 est. | NCT07625215 |
| Darolutamide | 1 | 1 | Oct 2028 est. | NCT07450599 |
| Regorafenib (Stivarga, BAY73-4506) | 1 | — | Apr 2028 est. | NCT06246643 |
Phase 121 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| 225Ac-PSMA-Trillium (BAY3563254) | 1 | 1 | Nov 2028 est. | NCT06217822 |
| AB-1001 Gene Therapy | 1 | — | — | NCT05541627 |
| AB-1003 dose level 1 | 1 | — | Dec 2028 est. | NCT05230459 |
| AB-1009 (GAA Gene) | 1 | 1 | Sept 2028 est. | NCT07282847 |
| Aspirin | 1 | 1 | Nov 2026 est. | NCT07652723 |
| BAY 3547926 | 1 | 1 | Jul 2029 est. | NCT06764316 |
| BAY 3713372 | 1 | 1 | Jun 2029 est. | NCT06914128 |
| BAY 3771249 | 1 | 1 | Jul 2029 est. | NCT07535112 |
| BAY2599023 (DTX201) | 1 | — | — | NCT03588299 |
| BAY2927088_formulation A | 1 | 1 | — | NCT05099172 |
| BAY2965501 | 1 | — | — | NCT05614102 |
| BAY3375968 | 1 | — | Apr 2027 est. | NCT05537740 |
| BAY3389934 | 1 | 1 | Dec 2026 est. | NCT06854640 |
| BAY3498264 | 1 | 1 | Apr 2027 est. | NCT06659341 |
| BAY3546828 | 1 | — | Jun 2027 est. | NCT06052306 |
| Elinzanetant (BAY 3427080) treatment A | 1 | 1 | Feb 2027 est. | NCT07762287 |
| Larotrectinib (Vitrakvi, BAY2757556) | 1 | — | — | NCT02637687 |
| Metformin | 1 | — | Sept 2026 est. | NCT07753252 |
| Nitroglycerin spray | 1 | — | May 2027 est. | NCT07431294 |
| Nurandociguat (BAY3283142) old tablet - SD | 1 | 1 | Oct 2026 est. | NCT07722585 |
| OpCT-001 | 1 | 1 | Oct 2029 est. | NCT06789445 |
Phase 43 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Acoramidis | 2 | 2 | Jul 2027 est. | NCT07298044 · NCT07791160 |
| Darolutamide (Nubeqa, BAY1841788) | 2 | 1 | Apr 2027 est. | NCT05348876 · NCT04464226 |
| Radium-223 dichloride (Xofigo, BAY88-8223) | 1 | — | — | NCT04597125 |
Derived from 61 active trials Bayer leads; 61 name an intervention, folding into 38 phased drugs. 8 interventions carry no registry phase (observational studies, tests and devices) and are not shown. This is ComplyRx's reading of the registry, not Bayer's own pipeline disclosure.
Bayer trials
The 50 most significant of Bayer's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the BodyNCT07753252Metformin | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 40 est. | 21 Sept 2026 |
| Double-DAREA Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology ClinicsNCT07406282Darolutamide | — | Not yet scored | OngoingRecruiting | 1,400 est. | 30 Sept 2026 |
| IN-REALITYAn Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical PracticeNCT06763146Finerenone (Kerendia, BAY948862) | — | Locked · track to reveal | OngoingActive, not recruiting | 1,200 est. | 30 Sept 2026 |
| INFORMAn Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and SwedenNCT06053749Avonex (IFNβ-1-a, Biogen Netherlands B.V) | — | Not yet scored | OngoingActive, not recruiting | 4 est. | 30 Sept 2026 |
| A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the BodyNCT07722585Nurandociguat (BAY3283142) old tablet - SD | Phase 1 | Not yet scored | OngoingRecruiting | 18 est. | 28 Oct 2026 |
| SHIELD-ETAn Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health OutcomesNCT07795606Estrogen therapy | — | Not yet scored | OngoingNot yet recruiting | 456,000 est. | 30 Oct 2026 |
| Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI TherapyNCT07291700Hydrotalcite (Talcid, BAYX002833) | — | Not yet scored | OngoingRecruiting | 167 est. | 31 Oct 2026 |
| A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care SettingNCT05348733Kerendia (Finerenone, BAY94-8862) | — | Locked · track to reveal | OngoingActive, not recruiting | 4,613 est. | 5 Nov 2026 |
| A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy ParticipantsNCT07652723Aspirin | Phase 1 | Not yet scored | OngoingRecruiting | 16 est. | 11 Nov 2026 |
| TARAAn Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in AustraliaNCT07223372 | — | Not yet scored | OngoingRecruiting | 1,000 est. | 30 Nov 2026 |
| A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced CoagulopathyNCT06854640BAY3389934 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 36 est. | 25 Dec 2026 |
| RE-ENGAGEAn Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical CareNCT06874114 | — | Not yet scored | OngoingActive, not recruiting | 700 est. | 31 Dec 2026 |
| HEM-POWREvaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia ANCT03932201Damoctocog alfa pegol (Jivi, Bay94-9027) | — | Not yet scored | OngoingActive, not recruiting | 371 est. | 31 Dec 2026 |
| A Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung MachineNCT06772025No investigational study intervention | Na | Locked · track to reveal | OngoingRecruiting | 200 est. | 31 Jan 2027 |
| A Methodological Study to Learn More About Kidney Function in Healthy People and in People With Reduced Kidney FunctionNCT07368712No investigational study intervention | Na | Locked · track to reveal | OngoingRecruiting | 50 est. | 19 Feb 2027 |
| Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study ParticipantsNCT07762287Elinzanetant (BAY 3427080) treatment A | Phase 1 | Locked · track to reveal | OngoingRecruiting | 100 est. | 22 Feb 2027 |
| exPDite-2A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's DiseaseNCT06944522bemdaneprocel | Phase 3 | Locked · track to reveal | OngoingRecruiting | 102 est. | Mar 2027 |
| An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)NCT06315556Aflibercept (Eylea) | — | Not yet scored | OngoingRecruiting | 200 est. | 31 Mar 2027 |
| JOIHAAn Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.NCT05643560Damoctocog alfa pegol (Jivi, BAY94-9027) | — | Not yet scored | OngoingActive, not recruiting | 33 est. | 31 Mar 2027 |
| HA-SAFEStudy to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent BleedingNCT04461639Damoctocog alfa pegol (Jivi, BAY94-9027) | — | Not yet scored | OngoingActive, not recruiting | 62 est. | 31 Mar 2027 |
| FIONAA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and ProteinuriaNCT05196035Finerenone (Kerendia, BAY94-8862) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 219 est. | 10 Apr 2027 |
| A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C MutationNCT06659341BAY3498264 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 104 est. | 26 Apr 2027 |
| A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)NCT05348876Darolutamide (Nubeqa, BAY1841788) | Phase 4 | Locked · track to reveal | OngoingRecruiting | 50 est. | 29 Apr 2027 |
| A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or DarolutamideNCT07672119 | — | Not yet scored | OngoingRecruiting | 3,000 est. | 29 Apr 2027 |
| A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsNCT05537740BAY3375968 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 129 est. | 30 Apr 2027 |
| A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery DiseaseNCT07431294Nitroglycerin spray | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 36 est. | 7 May 2027 |
| A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT06052306BAY3546828 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 232 est. | 8 Jun 2027 |
| Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)NCT04519619Aflibercept (Eylea, BAY86-5321) | — | Not yet scored | OngoingRecruiting | 480 est. | 30 Jun 2027 |
| A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal AnemiaNCT04899661Molidustat (Musredo, BAY85-3934) | — | Not yet scored | OngoingActive, not recruiting | 1,081 est. | 30 Jun 2027 |
| ACO-SWITCHA Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to AcoramidisNCT07298044Acoramidis | Phase 4 | Locked · track to reveal | OngoingRecruiting | 50 est. | 15 Jul 2027 |
| ARASTEPA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesNCT05794906Darolutamide (BAY1841788, Nubeqa) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 985 est. | 30 Jul 2027 |
| An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world SettingNCT06148935Vericiguat (Verquvo, BAY1021189) | — | Not yet scored | OngoingRecruiting | 1,350 est. | 31 Aug 2027 |
| The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula EdemaNCT06075147Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | — | Not yet scored | OngoingActive, not recruiting | 2,500 est. | 30 Sept 2027 |
| SOHO-02A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277Sevabertinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 444 est. | 28 Oct 2027 |
| ASSESSA Study to Learn About How Well BAY 3401016 Works in Adults With Alport SyndromeNCT07211685BAY 3401016 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 60 est. | 29 Nov 2027 |
| A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world ConditionsNCT05666518Vericiguat (Verquvo, BAY1021189) | — | Not yet scored | OngoingRecruiting | 1,400 est. | 31 Dec 2027 |
| ACO-MONITORSingle-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-MonitorNCT07557147Luscii | — | Locked · track to reveal | OngoingNot yet recruiting | 60 est. | 28 Feb 2028 |
| An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in KoreaNCT06334120Darolutamide (Nubeqa, BAY1841788) | — | Not yet scored | OngoingRecruiting | 600 est. | 31 Mar 2028 |
| A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer StudiesNCT06246643Regorafenib (Stivarga, BAY73-4506) | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 13 est. | 27 Apr 2028 |
| ACO-REALA Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world SettingNCT07235462Acoramidis (356 mg film-coated tablets) | — | Locked · track to reveal | OngoingRecruiting | 2,000 est. | 30 Apr 2028 |
| PIAPrescriptive Infusion Algorithm (PIA)NCT07215403Prescriptive Infusion Algorithm | Phase 2 | Locked · track to reveal | OngoingNot yet recruiting | 18 est. | 30 Apr 2028 |
| Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by BayerNCT04464226Darolutamide (Nubeqa, BAY1841788) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 402 est. | 26 Jun 2028 |
| FIONA OLEA Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaNCT05457283Finerenone (Kerendia, BAY94-8862) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 100 est. | 1 Aug 2028 |
| REGENERATE-PDA Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)NCT06285643AAV2-GDNF gene therapy | Phase 2 | Locked · track to reveal | OngoingRecruiting | 127 est. | 31 Aug 2028 |
| A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)NCT07282847AB-1009 (GAA Gene) | Phase 1 | Locked · track to reveal | OngoingRecruiting | 12 est. | Sept 2028 |
| CHINANEOA Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.NCT07450599Darolutamide | Phase 2 | Locked · track to reveal | OngoingRecruiting | 250 est. | 15 Oct 2028 |
| PACE mHSPCA Study of Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in IndiaNCT07806591Darolutamide plus androgen deprivation therapy | — | Not yet scored | OngoingNot yet recruiting | 50 est. | 31 Oct 2028 |
| PAnTHAFirst-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT06217822225Ac-PSMA-Trillium (BAY3563254) | Phase 1 | Locked · track to reveal | OngoingRecruiting | 198 est. | 26 Nov 2028 |
| A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)NCT05230459AB-1003 dose level 1 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 9 est. | Dec 2028 |
| MOSAIC-TTRStudy of Acoramidis in Patients With Transthyretin Amyloid CardiomyopathyNCT07791160Acoramidis | — | Locked · track to reveal | OngoingRecruiting | 500 est. | 31 Dec 2028 |